The New Yorker: The Long Quest for Artificial Blood One of the most valuable substances in the world has never been replicated. Are we close? By Nicola Twilley See more here
Read More
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its…
Read More
Science: There Will Be Blood Is mimicking the cells that carry hemoglobin the key to a blood substitute? See more here
Read More
KaloCyte Closes Investment from New York Blood Center This funding will be used to support KaloCyte as it scales up in advance of human trials See more here
Read More